ORGENESIS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ORGENESIS INC and buy or sell other stocks, ETFs, and their options commission-free!

About ORGS

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. 

CEO
Vered Caplan
CEOVered Caplan
Employees
146
Employees146
Headquarters
Germantown, Maryland
HeadquartersGermantown, Maryland
Founded
2008
Founded2008
Employees
146
Employees146

ORGS Key Statistics

Market cap
18.77M
Market cap18.77M
Price-Earnings ratio
-4.65
Price-Earnings ratio-4.65
Dividend yield
Dividend yield
Average volume
194.28K
Average volume194.28K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.08
52 Week high$1.08
52 Week low
$0.25
52 Week low$0.25

Stock Snapshot

ORGENESIS INC(ORGS) stock is priced at $0.40, giving the company a market capitalization of 18.77M. It carries a P/E multiple of -4.65.

On 2026-07-25, ORGENESIS INC(ORGS) stock opened at —, reached a high of —, and a low of —.

ORGENESIS INC(ORGS) shares are trading with a volume of 0, against a daily average of 194.28K.

In the last year, ORGENESIS INC(ORGS) shares hit a 52-week high of $1.08 and a 52-week low of $0.25.

In the last year, ORGENESIS INC(ORGS) shares hit a 52-week high of $1.08 and a 52-week low of $0.25.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.